BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33087400)

  • 1. Aurora kinases in ovarian cancer.
    Pérez-Fidalgo JA; Gambardella V; Pineda B; Burgues O; Piñero O; Cervantes A
    ESMO Open; 2020 Oct; 5(5):e000718. PubMed ID: 33087400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics.
    Gupta D; Kumar M; Saifi S; Rawat S; Ethayathulla AS; Kaur P
    Int J Biol Macromol; 2024 Apr; 265(Pt 2):130913. PubMed ID: 38508544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Aurora kinases in ovarian cancer.
    Fu S; Hu W; Kavanagh JJ; Bast RC
    Expert Opin Ther Targets; 2006 Feb; 10(1):77-85. PubMed ID: 16441230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting aurora kinases in cancer treatment.
    Kelly KR; Ecsedy J; Mahalingam D; Nawrocki ST; Padmanabhan S; Giles FJ; Carew JS
    Curr Drug Targets; 2011 Dec; 12(14):2067-78. PubMed ID: 21777198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora kinases: new targets for cancer therapy.
    Carvajal RD; Tse A; Schwartz GK
    Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora B: a new prognostic marker and therapeutic target in cancer.
    Portella G; Passaro C; Chieffi P
    Curr Med Chem; 2011; 18(4):482-96. PubMed ID: 21143115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer.
    Stefani A; Piro G; Schietroma F; Strusi A; Vita E; Fiorani S; Barone D; Monaca F; Sparagna I; Valente G; Ferrara MG; D'Argento E; Di Salvatore M; Carbone C; Tortora G; Bria E
    Front Oncol; 2022; 12():1026020. PubMed ID: 36387232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.
    Ciccone MA; Maoz A; Casabar JK; Machida H; Mabuchi S; Matsuo K
    Expert Opin Investig Drugs; 2016 Jul; 25(7):781-96. PubMed ID: 27101098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
    Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
    Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with aurora kinase inhibitors: a review.
    Boss DS; Beijnen JH; Schellens JH
    Oncologist; 2009 Aug; 14(8):780-93. PubMed ID: 19684075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of different pH milieu on the structure and function of human Aurora kinase B protein (AURK-B): Amalgamation of both spectroscopic and computational approach.
    Gupta D; Kumari R; Kumar M; Singh M; Rawat S; Ethayathulla AS; Kaur P
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 May; 312():124047. PubMed ID: 38394881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
    Lassus H; Staff S; Leminen A; Isola J; Butzow R
    Gynecol Oncol; 2011 Jan; 120(1):11-7. PubMed ID: 20937525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Aurora kinase inhibitors in cancer research and therapy.
    Cicenas J
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):1995-2012. PubMed ID: 26932147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora kinases as targets for cancer therapy.
    Mountzios G; Terpos E; Dimopoulos MA
    Cancer Treat Rev; 2008 Apr; 34(2):175-82. PubMed ID: 18023292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
    Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Aurora-A inhibitors in cancer therapy.
    Agnese V; Bazan V; Fiorentino FP; Fanale D; Badalamenti G; Colucci G; Adamo V; Santini D; Russo A
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi47-52. PubMed ID: 17591831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora kinase family: a new target for anticancer drug.
    Macarulla T; Ramos FJ; Tabernero J
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):114-22. PubMed ID: 18537754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Aurora kinases: role in cell transformation and tumorigenesis.
    Katayama H; Brinkley WR; Sen S
    Cancer Metastasis Rev; 2003 Dec; 22(4):451-64. PubMed ID: 12884918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora kinase inhibitors: a patent review (2014-2020).
    Jing XL; Chen SW
    Expert Opin Ther Pat; 2021 Jul; 31(7):625-644. PubMed ID: 33573401
    [No Abstract]   [Full Text] [Related]  

  • 20. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer.
    Hu W; Kavanagh JJ; Deaver M; Johnston DA; Freedman RS; Verschraegen CF; Sen S
    Oncol Res; 2005; 15(1):49-57. PubMed ID: 15839305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.